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1005-5 Endotheiiai Shear Stress identified in Vivo Within the 
Stent is Related to in-Stent Aestenosis and Remodeling 
of Stented Coronary Arteries 
&$tJQ&y, Ahmet U. Coskun, Charles L. Feldman, Maureen E. Clark. Milan Sanka, 
Andreas Wahle, Olusegun J. Ilegbusi. Jeffrey J. Popma, Richard E. Kuntz, Peter H. 
Stone, Brigham 8 Women’s Hospital, Boston, Massachuseffs, Northeastern Universi?: 
Boston, Massachusetts. 
Background: Endothelial shear stress (ESS) is a potent stimulus for regulating endothe- 
lial cell activation and the signals for vascular smooth muscle cell proliferation. However, 
the relationship of ESS to the subsequent development of instent restenosis in-viva has 
not been studied previously. The purpose of this study was to relate ESS measured at 
baseline to instent restenosis. Methods: We studied 3 patients after coronary artery 
stenting at baseline and 6 months. The 3-D anatomy of the stented segment was deter- 
mined using intracoronary ultrasound, biplane angiography, and coronary flow measure- 
ments. The lumen was reassembled in accurate 3-D space; local ESS was calculated 
using computational fluid dynamics. Outer vessel dimensions (external elastic lamina 
[EEL]) and the plaque (difference between EEL and the lumen) were similarly recon- 
structed. Changes in the artery at 6 mos were assessed by general linear regression 
accounting for repeated measurements. Results: Increasing ESS was associated with 
plaque progression and positive remodeling (all pcO.01). Lumen narrowing was least in 
the middle (physiological) ranges of ESS (9-26 dyne/cmZ) and greatest with low and high 
shear stress. Conclusions: These results show that stented coronary arteries respond to 
ESS within 6 mos. These changes are important in restenosis and arterial remodeling. 
This technique could be used to determine whether restenosis can be prevented by inter- 
ventions that are deployed to yield ESS in the physiological range. 
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1005-6 A Novel Preparation of Systemic Paciitaxei Reduces in- 
Stent Restenosis in the Rabbit 
Michael, Charanjit Khurana. Frank D. Kolodgie, Eduardo Acampado, Neil Desai, 
Patrick Soon-Shiong, Andrew Farb. Renu Virmani, Armed Forces lnsfitufe of Pathology, 
Washington, Dist. of Columbia, American SioScience Inc., Santa Monica, California. 
Background: Local delivery of paclitaxel (PXL) from drug-coated stents reduces in-stent 
restenosis at 26 days in the rabbit. A saline-reconstitutable systemic intravascular prepa- 
ration of PXL would provide uniform drug delivery at the Stent treatment site and allow for 
repetitive dosing. However currently available PXL is dissolved in toxic excipients such 
as cremophor and ethanol, which cause hypersensitivity. American BioScience has 
recently developed an albumin-based nanoparticle (n) formulation of PXL (nPXL), which 
is free of toxic solvents. Methods: 16 NZW rabbits underwent bilateral iliac artery stenting 
followed by an infusion of 2.5,3.5, or 5.0 mgikg nPXL through a catheter placed proximal 
to the stents or no treatment (control). Results: At 26 days, nPXL resulted in a dose- 
dependent reduction in neointima, accompanied by a concomitant increase in PMN on 
the intimal surface (table). Cellular proliferation was significantly greater in the 5.0 nPXL 
mglkg group vs. control (1.5% vs 0.67%, p<O.O2). nPXL-treated arteries demonstrated 
5060% endothelialization of the stent surface. Blood leukocyte count remained within 
normal limits throughout the experiment. Conclusion: A single injection of nPXL inhibits 
in-stent neointimal growth, similar to stent-based local delivery. Systemic nPXL offers a 
simplified drug-delivery regimen and allows for repeat dosing which may produce sus- 
tained neointimal suppression. Long-term (3 month) studies are ongoing with single and 
repeat dosing. 
PMN = Pofymorphonuclear Leukocytes. Values are meanrSEM 
Neointimal Thickness Neointimal Area % Stenosis Total Surface 
(mm) (mm*) PMN 
Control 0.126ti.01 1.5610.07 25.91tl .l 10.6f6.0 
2.5 mg/kg 0.104+0.01 1.3oH).O6 23.ti1.5 21.3?12 
3.5 mg/kg 0.066iO.01 1.22iO.07’ 20.9fl.3 23.9+11 
5.0 mg/kg 0.067*0.01* 1.2ofo.06 20.1*0.69 36&l 6 
* P vs. control < 0.004 i 0.02 0.01 NS 
1005-7 Pathological and Clinical Outcome of Long-Term 
intracoronary Stenting: is its Efficacy Permanent? 
Katsumi IIIPUQ, Kenji Ando, Kenichi Abe, Shinichi Shirai. Masashi Iwabuchi, Hiroyoshi 
Yokoi, Hiroyoshi Yokoi, Yoshihisa Nakagawa, Naoya Hamasaki, Takeshi Kimura, 
Hideyuki Nosaka. Masakiyo Nobuyoshi, Kokura MemorialHospital, Kitakyushu, Japan. 
Although coronary stenting effectively reduces clinical cardiac events for as long as 3 
years, longer-term efficacy has not yet been established. We reported that angiographic 
regression of luminal narrowing occurred 6 months to 3 years after Palmaz-Schatz (PS) 
stenting. However after 4 or more years lesions progressed gradually and late restenosis 
was observed in 26.7% of 122 lesions PS-stented within the past 10 years: in 11 lesions 
the stenosis was extremely severe or totally occluded. To have a deeper insight of these 
phenomena, 31 coronary artery specimens obtained from 27 necropsied patients expir- 
ing 1 to 7 years after PS stenting. were examined for histopathological and immunohis- 
tochemical studies. Chronic inflammatory cell infiltration, that included T lymphocytes (T 
cells), macrophages (MPs) and multinucleated giant cells was observed around the 
stent struts in the great majority even in absence of restenosis. Lesions that had 
regressed within a year after PS stenting, featured spindle-shaped smooth muscle cells 
(SMCs) along the luminal surface, completely covered by regenerated endothelial cells; 
the intercellular spaces contained dense collagenous tissue, and inflammatory 
responses were still evident around the struts. In the non-stenotic neointima after more 
than 3 years post-PS stenting, the SMCs had become atrophic and abundant prolifera- 
tion of co1 lagen fibers was evident instead. lmmunohistochemically, the presence of a 
small number of helper/inducer T cells and slight MPs infiftration were evident adjacent to 
the stent struts. In arteries stented more than 5 years before, prominent infiltration by 
lipid-laden MPs was observed around the struts which had collagen-degrading matrix 
metallopmteinases immunoreactivity. In 2 of these arteries, the luminal surface of the 
sites where the P&tent was located was focally eroded and non-occlusive thrombi con- 
sisting of platelets were observed at these portions. 
These findings suggest that the metal of PS stent evokes a remarkable foreign body 
inflammatory reaction. The residual chronic inflammatory cells around the struts may 
cause new and indolent atherosclerotic changes that induce plaque vulnerability. 
1005-8 Small Proximal Vessels Are Not Always Small: An 
intravascular Ultrasound Study 
Yoshio Kobava&i, lssam Moussa, Makoto Hirose. Farzana Arif. Octavia Balan, Arlene 
Reyes, Mohamed Mohamed, Milena Adamian, Roxana Mehran, George Dangas, 
Alexandra J. Lansky, Gregg W. Stone, Martin 8. Leon, Jeffrey W. Moses, Gary S. Mints, 
Cardiovascular Research Foundation, New York, New York. 
Background: Angiographically small vessels may be large when evaluated by intravascu- 
lar ultrasound (IVUS). 
Methods: Pre-intervention IVUS was performed in 177 angiographically small vessels 
(~3.0 mm by QCA) in the proximal segment of the major coronary arteries. The lesions 
were divided into two groups according to the difference in reference vessel size 
between QCA and IVUS [distal reference minimal vessel diameter (VD)]: 1) VD differ- 
ence (IVUS - QCA) a.5 mm (n=119) and 2) VD difference co.5 mm (n=56). IVUS-guided 
balloon angioplasty or stenting was perfoned in the lesions, 
Results: In multivariate analysis, LAD or RCA lesion (p=O.O5) and reference vessel diam- 
eter by QCA (p=O.O7) were predictors of large difference in reference vessel size. 
Conclusion: In angiographically small major proximal vessels, reference vessel size is 
underestimated in 67% of the lesions. In those vessels, IVUS-guided intervention should 
be performed to select appropriate (larger) balloon or stent sizes in order to optimize final 
lumen dimensions. 
Diabetes mellitus (%) 
LAD (%) 
Balloon/vessel ratio 
QCA 
Lesion length (mm) 
Reference diam (mm) 
Pre-MLD (mm) 
Final MLD (mm) 
IVUS 
Prox. minimal VD (mm) 
Dist. minimal VD (mm) 
Pre-lumen CSA at lesion (mm’) 
Final lumen CSA (mm’) 
Perforation (%) 
1 -month MACE (%) 
Difference co.5 Difference ~0.5 p value 
27 36 0.3 
51 66 0.03 
1.20i0.16 1.4M0.23 <O.Ol 
12.w6.2 11.6k7.7 0.3 
2.71M.27 2.56fl.35 co.01 
0.81fo.40 0.66+0.36 0.4 
2.74H.50 3.02iO.52 co.01 
3.4fl.6 3.910.5 co.01 
2.9fo.4 3.7+0.6 <O.Ol 
2&l .l 2.4k1.2 0.4 
5.9f1.4 7.ot1.7 <O.Ol 
1.7 0 0.2 
1.7 0 0.2 
